Johns Hopkins University

National Yang Ming Chiao Tung University

Academia Sinica

Erimos Pharmaceuticals, LLC

David Mold

Ru Chih C Huang

Yu-Chuan Liang

Jong Ho Chun

Yu-Ling Lin

Jonathan Daniel Heller

Kuang-Wen Liao

Jih Ru Hwu

Ru Chih Huang

Chih-Chuan Chang

Neil Frazer

Christopher Ruland

Ming Hua Hsu

Szu Chun Wu

Richard Park

Elaine Lin

Tiffany Jackson

Chien-Hsien Lai

Kunag-Wen Liao

The present invention provides novel pharmaceutical formulations comprising derivatives of NDGA, including MN (tetra-0-methyl nordihydroguaiaretic acid) and temozolomide and their use in the inhibition and treatment of neoplastic diseases, including glioblastoma multiforme, lung and other cancers.

Formulations of terameprocol and temozolomide and their use in stimulation of humoral immunity in tumors

The present invention provides pharmaceutical compositions comprising derivatives of NDGA, including M4N (tetra-O-methyl nordihydroguaiaretic acid) and sorafenib and their use in the inhibition and treatment of neoplastic diseases, such as liver cancer, colon cancer, breast cancer, brain cancers and ovarian cancers, for example, in a subject. Compositions comprising derivatives of NDGA, including M4N, sorafenib and additional therapeutic agents are also provided.

Compositions comprising NDGA derivatives and sorafenib and their use in treatment of cancer

Novel compounds which are derivatives of tetra-O-methyl nordihydroguaiaretic acid (NDGA), as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof are provided. These NDGA derivatives have a nitroimidazole moiety and these derivatives show preferential toxicity to hypoxic cells as hypoxic cytotoxins. Their cytotoxicity toward hypoxic cells is a result of abstraction of hydrogen from target molecules by free radicals formed in the reduction of the nitro group. This makes the disclosed compounds an effective anti cancer drug because hypoxic cells are generally considered to be more resistant to anti cancer drugs than normal cells. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment for cancers, including hepatocellular carcinoma, breast cancer and prostate cancer, are also provided.

Conjugates of nitroimidazoles and their use as chemotherapeutic agents

The present invention provides kits, methods and compositions for the treatment of tumor and other proliferative diseases such as tumors. The compositions herein contain a substantially pure preparation of at least one catecholic butane, including, for example, NDGA compounds in a pharmaceutically acceptable carrier or excipient. The catecholic butane such as NDGA or its derivatives are administered to one or more subjects in need of treatment by a route other than direct injection into the affected tissues or topical application on affected tissues.

Methods for delivery of catecholic butanes for treatment of tumors

Growing community of inventors

Baltimore, MD, United States of America

David Mold